Logo image of FENC

FENNEC PHARMACEUTICALS INC (FENC) Stock Fundamental Analysis

USA - NASDAQ:FENC - CA31447P1009 - Common Stock

8.7 USD
+0.3 (+3.57%)
Last: 9/25/2025, 8:00:00 PM
8.7 USD
0 (0%)
After Hours: 9/25/2025, 8:00:00 PM
Fundamental Rating

2

FENC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 538 industry peers in the Biotechnology industry. FENC has a bad profitability rating. Also its financial health evaluation is rather negative. FENC has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FENC had negative earnings in the past year.
In the past year FENC has reported a negative cash flow from operations.
In the past 5 years FENC always reported negative net income.
FENC had negative operating cash flow in 4 of the past 5 years.
FENC Yearly Net Income VS EBIT VS OCF VS FCFFENC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

FENC has a Return On Assets of -26.83%. This is in the better half of the industry: FENC outperforms 70.63% of its industry peers.
Industry RankSector Rank
ROA -26.83%
ROE N/A
ROIC N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FENC Yearly ROA, ROE, ROICFENC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

With an excellent Gross Margin value of 89.89%, FENC belongs to the best of the industry, outperforming 91.64% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for FENC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FENC Yearly Profit, Operating, Gross MarginsFENC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

FENC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FENC has more shares outstanding
The debt/assets ratio for FENC has been reduced compared to a year ago.
FENC Yearly Shares OutstandingFENC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FENC Yearly Total Debt VS Total AssetsFENC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -3.41, we must say that FENC is in the distress zone and has some risk of bankruptcy.
FENC has a Altman-Z score (-3.41) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.41
ROIC/WACCN/A
WACCN/A
FENC Yearly LT Debt VS Equity VS FCFFENC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

FENC has a Current Ratio of 4.85. This indicates that FENC is financially healthy and has no problem in meeting its short term obligations.
FENC has a Current ratio (4.85) which is in line with its industry peers.
FENC has a Quick Ratio of 4.59. This indicates that FENC is financially healthy and has no problem in meeting its short term obligations.
FENC has a Quick ratio (4.59) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.85
Quick Ratio 4.59
FENC Yearly Current Assets VS Current LiabilitesFENC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

FENC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -520.00%.
The Revenue for FENC has decreased by -31.89% in the past year. This is quite bad
EPS 1Y (TTM)-520%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
Revenue 1Y (TTM)-31.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.91%

3.2 Future

Based on estimates for the next years, FENC will show a very strong growth in Earnings Per Share. The EPS will grow by 240523.00% on average per year.
FENC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.44% yearly.
EPS Next Y169782103072165900%
EPS Next 2Y11530794814.79%
EPS Next 3Y28002300%
EPS Next 5Y240523%
Revenue Next Year-17.14%
Revenue Next 2Y12.45%
Revenue Next 3Y14.55%
Revenue Next 5Y24.44%

3.3 Evolution

FENC Yearly Revenue VS EstimatesFENC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
FENC Yearly EPS VS EstimatesFENC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

FENC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 11.79, the valuation of FENC can be described as reasonable.
96.47% of the companies in the same industry are more expensive than FENC, based on the Price/Forward Earnings ratio.
FENC is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.64, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 11.79
FENC Price Earnings VS Forward Price EarningsFENC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FENC Per share dataFENC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

FENC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FENC's earnings are expected to grow with 28002300.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11530794814.79%
EPS Next 3Y28002300%

More info and screens

0

5. Dividend

5.1 Amount

FENC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FENNEC PHARMACEUTICALS INC

NASDAQ:FENC (9/25/2025, 8:00:00 PM)

After market: 8.7 0 (0%)

8.7

+0.3 (+3.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners56.63%
Inst Owner Change1.33%
Ins Owners1.93%
Ins Owner Change0.74%
Market Cap242.12M
Analysts85.45
Price Target14.08 (61.84%)
Short Float %5.44%
Short Ratio21.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-71.86%
Min EPS beat(2)-199.56%
Max EPS beat(2)55.84%
EPS beat(4)1
Avg EPS beat(4)-101.98%
Min EPS beat(4)-199.56%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-153.59%
EPS beat(12)4
Avg EPS beat(12)-110.94%
EPS beat(16)6
Avg EPS beat(16)-92.6%
Revenue beat(2)1
Avg Revenue beat(2)2.15%
Min Revenue beat(2)-0.57%
Max Revenue beat(2)4.87%
Revenue beat(4)1
Avg Revenue beat(4)-18.28%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)4.87%
Revenue beat(8)4
Avg Revenue beat(8)-6.65%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.81%
PT rev (3m)7.81%
EPS NQ rev (1m)-33.96%
EPS NQ rev (3m)-28.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-37.57%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)3.31%
Revenue NY rev (1m)-0.78%
Revenue NY rev (3m)-0.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.79
P/S 7.27
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)0.74
Fwd EY8.48%
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS1.2
BVpS-0.27
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.83%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.89%
FCFM N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.85
Quick Ratio 4.59
Altman-Z -3.41
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-520%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
EPS Next Y169782103072165900%
EPS Next 2Y11530794814.79%
EPS Next 3Y28002300%
EPS Next 5Y240523%
Revenue 1Y (TTM)-31.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.91%
Revenue Next Year-17.14%
Revenue Next 2Y12.45%
Revenue Next 3Y14.55%
Revenue Next 5Y24.44%
EBIT growth 1Y-258.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2876.34%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.63%
OCF growth 3YN/A
OCF growth 5YN/A